EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Differential impact of asparaginase discontinuation on outcomes of children with T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma

Hisashi Ishida iD, Toshihiko Imamura, Ryoji Kobayashi iD, Yoshiko Hashii, Takao Deguchi, Takako Miyamura, Megumi Oda, Masaki Yamamoto, Keiko Okada, Hideki Sano, Katsuyoshi Koh, Yuki Yuza and 8 more

Cancer Medicine · 2024-06 · 13 (12)

DOI: 10.1002/cam4.7246 ↗

At a glance

Journal article in Cancer Medicine, published online on 2024-06-18. Written by Hisashi Ishida and 19 co-authors. Institution: Department of Pediatrics, Okayama University Hospital, Okayama, Japan. Major MEDLINE topics: Asparaginase, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Cited 6 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: Grants for Clinical Cancer Research from the Ministry of Health, Labor and Welfare of Japan.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Asparaginase is essential for treating T‐cell acute lymphoblastic leukemia (T‐ALL). Despite the ongoing debate on whether T‐ALL and T‐cell lymphoblastic lymphoma (T‐LBL) are the same disease entity or two distinct diseases, patients with T‐LBL often receive the same or similar treatment protocols as those with T‐ALL.

Methods

The outcomes of patients with or without L‐asparaginase discontinuation were retrospectively analyzed among four national protocols: Japan Association of Childhood Leukemia Study (JACLS) ALL‐02 and ALL‐97 for T‐ALL and Japanese Pediatric Leukemia/Lymphoma Study Group ALB‐NHL03 and JACLS NHL‐98 for T‐LBL. The hazard ratio (HR) was calculated with the Cox regression model by considering L‐asparaginase discontinuation as a time‐dependent variable.

Results

In total, 199 patients with T‐ALL, and 133 patients with T‐LBL were included. L‐asparaginase discontinuation compromised event‐free survival (EFS) of T‐ALL patients (ALL‐02: HR 3.32, 95% confidence interval [CI] 1.40–7.90; ALL‐97: HR 3.39, 95%CI 1.19–9.67). Conversely, EFS compromise was not detected among T‐LBL patients (ALB‐NHL03: HR 1.39, 95%CI 0.41–4.68; NHL‐98: HR 0.92, 95%CI 0.11–7.60).

Conclusion

The effects of L‐asparaginase discontinuation differed between T‐ALL and T‐LBL. We assume that the differential impact results from (1) the inherent differential response to L‐asparaginase between them and/or (2) a less stringent assessment of early treatment response in T‐LBL than in T‐ALL. Given the poor salvage rate of refractory or relapsed T‐ALL and T‐LBL, optimization of the frontline therapy is critical, and the current study provides a new suggestion for further treatment modifications. However, larger studies in contemporary intensified treatment protocols are required.

Subjects

MeSH terms (MEDLINE)

AsparaginasePrecursor T-Cell Lymphoblastic Leukemia-LymphomaHumansChildMaleFemaleChild, PreschoolRetrospective StudiesAdolescentInfantTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsJapanAntineoplastic Agents

Author keywords

T‐cell acute lymphoblastic leukemiaT‐cell lymphoblastic lymphomaacute pancreatitisallergyasparaginasechildren

Substances

AsparaginaseAntineoplastic Agents

Authors and institutions

  • Department of Pediatrics, Okayama University Hospital, Okayama, Japan.
  • Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
  • Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Sapporo, Japan.
  • Department of Pediatrics, Osaka International Cancer Institute, Osaka, Japan.
  • Division of Cancer Immunodiagnostics, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.

ORCID profiles: Hisashi Ishida, Ryoji Kobayashi

Funding

  • Grants for Clinical Cancer Research from the Ministry of Health, Labor and Welfare of Japan

Cite

APA

Ishida, H., Imamura, T., Kobayashi, R., Hashii, Y., Deguchi, T., Miyamura, T., Oda, M., Yamamoto, M., Okada, K., Sano, H., Koh, K., Yuza, Y., Watanabe, K., Nishimura, N., Takimoto, T., Moriya-Saito, A., Sekimizu, M., Suenobu, S., Sunami, S., & Horibe, K. (2024). Differential impact of asparaginase discontinuation on outcomes of children with T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma. Cancer Medicine, 13(12). https://doi.org/10.1002/cam4.7246

Vancouver

Ishida H, Imamura T, Kobayashi R, Hashii Y, Deguchi T, Miyamura T, et al. Differential impact of asparaginase discontinuation on outcomes of children with T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma. Cancer Medicine. 2024;13(12). doi:10.1002/cam4.7246

BibTeX
@article{Ishida2024,
  author = {Ishida, Hisashi and Imamura, Toshihiko and Kobayashi, Ryoji and Hashii, Yoshiko and Deguchi, Takao and Miyamura, Takako and Oda, Megumi and Yamamoto, Masaki and Okada, Keiko and Sano, Hideki and Koh, Katsuyoshi and Yuza, Yuki and Watanabe, Kenichiro and Nishimura, Noriyuki and Takimoto, Tetsuya and Moriya-Saito, Akiko and Sekimizu, Masahiro and Suenobu, Souichi and Sunami, Shosuke and Horibe, Keizo},
  title = {Differential impact of asparaginase discontinuation on outcomes of children with T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {12},
  doi = {10.1002/cam4.7246}
}
Start for free →